Lenograstim

Summary

Lenograstim (CHEMBL2109128) is an approved protein (ATC L03AA10) targeting CSF3R and CSF1R; indicated across 6 conditions including neoplasm and plasma cell myeloma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AA10
• Targets: 2 (CSF3R, CSF1R)
• Indications: 6 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109128
Name	Lenograstim
Type	Protein
Max phase	4
ATC	L03AA10

Also known as: G-csf (cho cell derived), Glycosylated recombinant g-csf, Granocyte, Granocyte-13, Granocyte-34, Lenograstim, Lenograstim (genetical recombination), Lenograstim rdna, Neutrogin, RG-CSF, LENOGRASTIM

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CSF3R	Granulocyte colony-stimulating factor receptor	Agonist		0.9%	Q99062
CSF1R	colony stimulating factor 1 receptor			0%	P07333
	Granulocyte macrophage colony-stimulating factor receptor	Agonist

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): CSF3R, CSF1R.

Top Reactome pathways

6 total, by targets touching each:

Pathway	Targets	Genes
Other interleukin signaling	2	CSF1R, CSF3R
Transcriptional Regulation by VENTX	1	CSF1R
Transcriptional regulation of granulopoiesis	1	CSF3R
Signaling by CSF3 (G-CSF)	1	CSF3R
Signaling by CSF1 (M-CSF) in myeloid cells	1	CSF1R
Inactivation of CSF3 (G-CSF) signaling	1	CSF3R

Dominant GO biological processes

GO term	Targets
signal transduction	2
positive regulation of cell population proliferation	2
cytokine-mediated signaling pathway	2
defense response	1
cell adhesion	1
neutrophil chemotaxis	1
regulation of myeloid cell differentiation	1
amelogenesis	1
positive regulation of protein phosphorylation	1
response to ischemia	1
inflammatory response	1
cell surface receptor protein tyrosine kinase signaling pathway	1
axon guidance	1
cell population proliferation	1
negative regulation of cell population proliferation	1

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
diffuse large B-cell lymphoma	3	MONDO:0018905	EFO:0000403
acute myocardial infarction	2	MONDO:0004781	EFO:0008583

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2/PHASE3	3
PHASE1/PHASE2	2
Not specified	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00499018	PHASE3	UNKNOWN	Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
NCT00650143	PHASE2/PHASE3	COMPLETED	Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction
NCT00932217	PHASE3	UNKNOWN	Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma
NCT01085058	PHASE2/PHASE3	COMPLETED	Predictive Value of the Cytocapacity Test Patients With Lymphoproliferative Diseases and High-dose Therapy
NCT01907009	PHASE2/PHASE3	TERMINATED	A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)
NCT02319135	PHASE3	COMPLETED	Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00379574	PHASE1/PHASE2	COMPLETED	Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
NCT00551122	PHASE1/PHASE2	UNKNOWN	Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
NCT01180322	PHASE2	COMPLETED	Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine
NCT05594433	PHASE1	RECRUITING	Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte)
NCT02184897	Not specified	UNKNOWN	Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization
NCT03498248	Not specified	UNKNOWN	Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

72 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R
AXITINIB	ChEMBL	Phase 4 (approved)	CSF1R
BOSUTINIB	ChEMBL	Phase 4 (approved)	CSF1R
BRIGATINIB	ChEMBL	Phase 4 (approved)	CSF1R
DASATINIB	ChEMBL	Phase 4 (approved)	CSF1R
ENTRECTINIB	ChEMBL	Phase 4 (approved)	CSF1R
FEDRATINIB	ChEMBL	Phase 4 (approved)	CSF1R
FILGOTINIB	ChEMBL	Phase 4 (approved)	CSF1R
IBRUTINIB	ChEMBL	Phase 4 (approved)	CSF1R
IMATINIB	ChEMBL	Phase 4 (approved)	CSF1R
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	CSF1R
NERATINIB	ChEMBL	Phase 4 (approved)	CSF1R
NILOTINIB	ChEMBL	Phase 4 (approved)	CSF1R
NINTEDANIB	ChEMBL	Phase 4 (approved)	CSF1R
PACRITINIB	ChEMBL	Phase 4 (approved)	CSF1R
PEXIDARTINIB	ChEMBL	Phase 4 (approved)	CSF1R
PONATINIB	ChEMBL	Phase 4 (approved)	CSF1R
QUIZARTINIB	ChEMBL	Phase 4 (approved)	CSF1R
SORAFENIB	ChEMBL	Phase 4 (approved)	CSF1R
SUNITINIB	ChEMBL	Phase 4 (approved)	CSF1R
SUNITINIB MALATE	ChEMBL	Phase 4 (approved)	CSF1R
VANDETANIB	ChEMBL	Phase 4 (approved)	CSF1R
ALVOCIDIB	ChEMBL	Phase 3	CSF1R
BRIVANIB	ChEMBL	Phase 3	CSF1R
CEDIRANIB	ChEMBL	Phase 3	CSF1R
DACTOLISIB	ChEMBL	Phase 3	CSF1R
DOVITINIB	ChEMBL	Phase 3	CSF1R
LESTAURTINIB	ChEMBL	Phase 3	CSF1R
LINIFANIB	ChEMBL	Phase 3	CSF1R
MASITINIB	ChEMBL	Phase 3	CSF1R
MOTESANIB	ChEMBL	Phase 3	CSF1R
PIMICOTINIB	ChEMBL	Phase 3	CSF1R
SEMAXANIB	ChEMBL	Phase 3	CSF1R
VATALANIB	ChEMBL	Phase 3	CSF1R
VIMSELTINIB	ChEMBL	Phase 3	CSF1R
ARRY-382	ChEMBL	Phase 2	CSF1R
BELVARAFENIB	ChEMBL	Phase 2	CSF1R
BMS-754807	ChEMBL	Phase 2	CSF1R
CC-115	ChEMBL	Phase 2	CSF1R
CENISERTIB	ChEMBL	Phase 2	CSF1R
CEP-11981	ChEMBL	Phase 2	CSF1R
CEP-32496	ChEMBL	Phase 2	CSF1R
CERDULATINIB	ChEMBL	Phase 2	CSF1R
DEFOSBARASERTIB	ChEMBL	Phase 2	CSF1R
DERAZANTINIB	ChEMBL	Phase 2	CSF1R
DORAMAPIMOD	ChEMBL	Phase 2	CSF1R
EDICOTINIB	ChEMBL	Phase 2	CSF1R
ELZOVANTINIB	ChEMBL	Phase 2	CSF1R
ENMD-2076	ChEMBL	Phase 2	CSF1R
ENRUPATINIB	ChEMBL	Phase 2	CSF1R
FORETINIB	ChEMBL	Phase 2	CSF1R
GZ-389988	ChEMBL	Phase 2	CSF1R
ILORASERTIB	ChEMBL	Phase 2	CSF1R
INIXACICLIB	ChEMBL	Phase 2	CSF1R
NARAZACICLIB	ChEMBL	Phase 2	CSF1R
NEFLAMAPIMOD	ChEMBL	Phase 2	CSF1R
ONATASERTIB	ChEMBL	Phase 2	CSF1R
PELITINIB	ChEMBL	Phase 2	CSF1R
R-406	ChEMBL	Phase 2	CSF1R